Research and development is the lifeblood of biotech companies. The potential for new drugs also serves as a primary factor driving biotech stocks higher and higher. That’s been the case for Celgene (NASDAQ:CELG), Ionis Pharmaceuticals (NASDAQ:IONS), and Ligand Pharmaceuticals (NASDAQ:LGND).
These three biotechs boast some of the most promising pipelines around. Here’s what sets Celgene, Ionis, and Ligand apart from the pack.
Image source: Getty Images.
Celgene: Strong candidates in multiple therapeutic areas
Celgene’s pipeline includes 15 late-stage programs plus two awaiting regulatory approval. Several of those studies are evaluating drugs already on the market in treating additional indications. However, Celgene also claims some new candidates with huge potential.
The big biotech has partnered with Acceleron Pharma on luspatercept. Analysts predict that the drug, which targets blood disorders beta-thalassemia and myelodysplastic syndromes (MDS), could reach peak annual sales of around $2 billion if approved.
Hot Biotech Stocks To Invest In 2019: Amgen Inc.(AMGN)
- [By Shane Hupp]
Investors sold shares of Amgen, Inc. (NASDAQ:AMGN) on strength during trading hours on Thursday. $63.15 million flowed into the stock on the tick-up and $134.51 million flowed out of the stock on the tick-down, for a money net flow of $71.36 million out of the stock. Of all stocks tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $2.11 for the day and closed at $185.79
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) is waiting for the FDA to review its Biologics License Application (BLA) for Aimovig (erenumab) for the prevention of migraine in patients experiencing four or more migraine days per month. The FDA has set a PDUFA date for May 17.
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.79 million shares from the previous level of 10.46 million. Shares were last seen at $170.00, in a 52-week trading range of $152.16 to $201.23.
- [By Stephan Byrd]
Private Capital Group LLC boosted its stake in Amgen, Inc. (NASDAQ:AMGN) by 1,703.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,362 shares of the medical research company’s stock after purchasing an additional 2,231 shares during the period. Private Capital Group LLC’s holdings in Amgen were worth $403,000 at the end of the most recent reporting period.
- [By Cory Renauer]
Sanofi took the assessment and started engaging end payers to see if any would offer easy reimbursement for a lower net price that reflects ICER’s assessment, and the industry listened. As of July 1, the partners will cut the net price of Praluent in return for straightforward access for around 25 million Americans covered by theExpress Scripts (NASDAQ:ESRX) national formulary. Thepharmacy benefits manager, and will also remove formulary access for its main competitor, Amgen’s (NASDAQ:AMGN) Repatha.
- [By Cory Renauer]
The Food and Drug Administration recently approved Aimovig fromAmgen (NASDAQ:AMGN) and Novartis (NYSE:NVS), the first of several high-profile new drug candidates with a similar mode of action.Teva Pharmaceuticals Industries (NYSE:TEVA)andEli Lilly(NYSE:LLY) have sent applications for similar drugs to the FDA and Alder’s starting to look like a terrier that showed up to a bullfight.
Hot Biotech Stocks To Invest In 2019: Alnylam Pharmaceuticals Inc.(ALNY)
- [By Keith Speights]
Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiranappears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs.
- [By Keith Speights]
I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick — but with a couple of qualifications. First, I didn’t think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.
- [By Sean Williams, Chuck Saletta, and Brian Feroldi]
So, which biotech stocks should you consider buying in June? That’s a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).
- [By Brian Orelli]
The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”
- [By Logan Wallace]
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company. However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”
- [By Keith Speights]
It’s not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum’s market cap is less than $350 million while Alnylam’s market cap is close to $10 billion.
Hot Biotech Stocks To Invest In 2019: Biogen Idec Inc(BIIB)
- [By Todd Campbell]
PTC Therapeutics (NASDAQ:PTCT) shares took off after updated data from a trial evaluatingrisdiplam suggested it could mount a stiff challenge toBiogen’s (NASDAQ:BIIB)and Ionis Pharmaceuticals'(NASDAQ:IONS)Spinrazafor the treatment of spinal muscular atrophy (SMA), a rare and life-threatening genetic disease. The data is solid, but a one-and-done SMA treatment is already in late-stage studies at Novartis’ (NYSE:NVS), and that therapy could become available as soon as 2019.
- [By Benzinga News Desk]
A distillery in a small Spanish town has claimed it invented the original Coca-Cola (NYSE: KO) recipe and now wants recognition: Link
Initial Jobless Claims For Week Ended May 25 221K vs 225K Economist Estimate, Down From 234K In Prior Week
Personal Income Apr. Up 0.3%, Personal Spending Up 0.6%
The Chicago PMI for May is schedule for release at 9:45 a.m. ET.
The pending home sales index for April will be released at 10:00 a.m. ET.
The Energy Information Administration’s weekly report on natural gas stocks in underground storage is schedule for release at 10:30 a.m. ET.
The Energy Information Administration’s weekly report on petroleum inventories will be released at 11:00 a.m. ET.
Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 12:30 p.m. ET.
Fed Governor Lael Brainard will speak at 1:00 p.m. ET.
Data on money supply for the recent week will be released at 4:30 p.m. ET.
Federal Reserve Bank of Dallas President Robert Kaplan is set to speak at 8:30 p.m. ET.
Canaccord upgrades Biogen (NASDAQ: BIIB) from Hold to Buy
Morgan Stanley upgrades Corning (NYSE: GLW) from Equal-Weight to Overweight
Morgan Stanley downgrades Micron (NASDAQ: MU) from Overweight to Equal-Weight
Cantor downgrades HealthEquity (NASDAQ: HQY) from Overweight to Neutral
This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.
- [By WWW.GURUFOCUS.COM]
For the details of Woodford Investment Management LLP’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Woodford+Investment+Management+LLP
These are the top 5 holdings of Woodford Investment Management LLPProthena Corp PLC (PRTA) – 11,557,614 shares, 37.95% of the total portfolio. Shares added by 0.25%Alkermes PLC (ALKS) – 5,270,428 shares, 27.32% of the total portfolio. Shares reduced by 30.52%Theravance Biopharma Inc (TBPH) – 10,898,879 shares, 23.64% of the total portfolio. Shares added by 1.41%Biogen Inc (BIIB) – 279,564 shares, 6.85% of the total portfolio. Shares reduced by 24.56%Evofem Biosciences Inc (EVFM) – 7,465,538
- [By Cory Renauer]
Biogen Inc.’s (NASDAQ:BIIB) Alzheimer’s disease hopeful topped the list last year, but repeated failures with experimental drugs that attack the disease from a similar angle have all flopped. Despite the risk, EvaluatePharma estimates aducanumab’s present value ataround$8.4 billion and this figure will rise or fall dramatically when the company reads off results of ongoing pivotal trials, probably in early 2020.
- [By Lisa Levin]
Analysts at Canaccord Genuity upgraded Biogen Inc. (NASDAQ: BIIB) from Hold to Buy.
Biogen shares rose 2.55 percent to close at $294.40 on Tuesday.
Hot Biotech Stocks To Invest In 2019: ArQule Inc.(ARQL)
- [By Joseph Griffin]
ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.
- [By Maxx Chatsko]
Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on ArQule (ARQL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Money Morning Staff Reports]
But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we’ll show you a small-cap stock with great profit potential in its future…
Penny Stock Current Share Price Law Month’s Gain
Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85%
Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40%
Vivis Inc. (Nasdaq: VVUS) $0.77 150.41%
Adomani Inc. (Nasdaq: ADOM) $1.49 137.68%
NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88%
Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06%
Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12%
ArQule Inc. (Nasdaq: ARQL) $4.88 90.74%
LiqTech International Inc. (NYSE: LIQT) $0.66 85.60%
Transenterix Inc. (NYSE: TRXC) $3.46 77.84%
While last month’s gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.
- [By Lisa Levin] Gainers
Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter.
Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants.
Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday.
SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday.
Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results.
Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter.
Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday.
Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday.
ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday.
Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday.
Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
- [By Ethan Ryder]
ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.